Tag: personalized cancer vaccines market share

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

Personalized Cancer Vaccines Market Revenue Growth On Track For A 6.4% CAGR Through 2030

The personalized cancer vaccines market size has experienced robust expansion in recent years. It is forecast to rise from $256.65 billion in 2025 to $273.05 billion in 2026, expanding at a compound annual growth rate (CAGR) of 6.4%. The increase observed in the historic period is largely due to advancements in cancer genomics, the substantial unmet need in oncology treatments, the inherent limitations of traditional cancer therapies, the expansion of immunotherapy research, and increased financial support for cancer research.

The personalized cancer vaccines market is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach $350.3 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.4%. This anticipated growth during the forecast period can be primarily ascribed to the wider adoption of personalized medicine, an increase in cancer incidence rates, advancements in neoantigen discovery, heightened collaboration among biotechnology companies, and favorable regulatory environments. Key trends expected within this period encompass a growing emphasis on personalized immunotherapy, increased application of genomic tumor profiling, the expansion of therapeutic cancer vaccines, greater integration with precision oncology, and elevated clinical trial activity for cancer vaccines.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=27057632&type=smp&name=Personalized%20Cancer%20Vaccines%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Personalized Cancer Vaccines Market Opportunity Drivers: What’s Unlocking New Revenue Potential?

The rising incidence of cancer is anticipated to drive expansion in the personalized cancer vaccine market in the future. Cancer is defined as a collection of illnesses marked by unregulated cell proliferation, capable of invading adjacent tissues and metastasizing throughout the body. The growing occurrence of cancer is fueled by factors such as demographic shifts towards older populations, evolving lifestyles, exposure to environmental agents, and advancements in diagnostic methods. This personalized cancer vaccine market contributes to cancer treatment by offering vaccines uniquely designed for individual patient tumor antigens, thereby boosting the immune system’s capacity to recognize and eradicate malignant cells. A notable example comes from July 2024, when the Australian Institute of Health and Welfare (AIHW), an Australia-based government body, reported an increase in cancer diagnoses in Australia, climbing from 160,570 cases in 2022 to 164,694 cases in 2023, which signifies a considerable rise year-on-year. Consequently, the growing frequency of cancer cases is fueling the expansion of the personalized cancer vaccine market.

Personalized Cancer Vaccines Market Segment Analysis: What Are The Core Market Categories?

The personalized cancer vaccines market covered in this report is segmented –

1) By Treatment Type: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines

2) By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Prostate Cancer, Cervical Cancer, Glioblastoma

3) By Mechanism Of Action: Tumor Associated Antigens (TAAs), Tumor Specific Antigens (TSAs), Somatic Mutations In Cancer Pharmacogenomics, Pharmacogenomics Towards Genomic Polymorphism, Other Mechanisms Of Action

4) By Route Of Administration: Injectables, Other Routes Of Administration

5) By End Use: Hospitals, Clinic, Other End Users

Subsegments:

1) By Preventive Cancer Vaccines: HPV Vaccines, Hepatitis B Vaccines, Combination Vaccines

2) By Therapeutic Cancer Vaccines: Dendritic Cell Vaccines, Peptide-Based Vaccines, DNA Vaccines, RNA Vaccines, Whole Cell Vaccines

Personalized Cancer Vaccines Market Innovation Trends Shaping Future Development

Major companies operating within the personalized cancer vaccine market are concentrating on developing sophisticated therapeutic solutions, including personalized immunotherapy aimed at specific patient tumor mutations, to enhance treatment accuracy and improve clinical outcomes. Personalized immunotherapy refers to bespoke cancer treatments that leverage a patient’s unique genetic and tumor mutation profile, often delivered via dendritic cell–based vaccines or neoantigen-targeted platforms, to generate a tailored immune response against malignant cells. For instance, in August 2024, UCLA Health, a US-based healthcare organization, initiated a groundbreaking clinical trial to evaluate a personalized cancer vaccine targeting the H3 G34 mutation in diffuse hemispheric gliomas, utilizing dendritic cells to stimulate immunity against the RNA disruptions caused by this aggressive mutation, offering a promising therapeutic avenue for adolescents and young adults who typically face limited treatment choices and poor survival rates.

Personalized Cancer Vaccines Market Top Companies Driving Competitive Growth

Major companies operating in the personalized cancer vaccines market are Moderna Inc., CureVac AG, BioNTech SE, Genentech Inc., Merck & Co. Inc., GlaxoSmithKline plc, Achilles Therapeutics Plc, Evaxion Biotech AS, Geneos Therapeutics Inc., ISA Pharmaceuticals BV, VAXIMM GmbH, EpiVax Therapeutics Inc., Personalis Inc., Catalent Inc., Gritstone bio Inc., Neon Therapeutics Inc., Nouscom AG, Vaccitech plc, Agenus Inc., Transgene SA

View The Full Personalized Cancer Vaccines Market Report:

https://thebusinessresearchcompany.com/report/personalized-cancer-vaccines-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Personalized Cancer Vaccines Market Geographic Spread And Regional Opportunities

North America was the largest region in the personalized cancer vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized cancer vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Personalized Cancer Vaccines Market Revenue Outlook: What CAGR Is Expected Through 2030?

In recent times, the personalized cancer vaccines sector has experienced robust expansion, with its valuation projected to rise from $256.65 billion in 2025 to $273.05 billion in 2026, representing a compound annual growth rate (CAGR) of 6.4%. This historical growth has been driven by progress in cancer genomics, the pressing demand for more effective oncology solutions, the constraints of conventional cancer treatments, an uptick in immunotherapy investigations, and amplified financial support for cancer research initiatives.

The personalized cancer vaccines market is projected to experience significant expansion over the coming years, reaching an estimated value of $350.3 billion by 2030, with a compound annual growth rate of 6.4%. This anticipated growth during the forecast period is driven by factors such as the broader uptake of personalized medicine, rising cancer incidence rates, advances in neoantigen identification, increased partnerships among biotechnology companies, and encouraging regulatory policies. Key trends shaping this period include a growing emphasis on tailored immunotherapies, wider application of genomic tumor profiling, expansion of therapeutic cancer vaccine offerings, deeper integration with precision oncology strategies, and heightened clinical trial activity focused on cancer vaccines.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19136&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Personalized Cancer Vaccines Market Growth Factors Supporting Long-Term Expansion

The growing incidence of cancer is anticipated to drive expansion in the personalized cancer vaccine market moving forward. Cancer is defined as a collection of conditions marked by the unchecked proliferation of cells, capable of invading adjacent tissues and metastasizing to distant organs. This rise in cancer cases is fueled by factors such as aging demographics, shifts in lifestyle patterns, exposure to environmental elements, and enhanced diagnostic technologies. The personalized cancer vaccine market aids in cancer treatment by creating customized vaccines based on individual tumor-specific antigens, thereby boosting the immune system’s capacity to detect and eradicate malignant cells. By way of illustration, data from the Australian Institute of Health and Welfare (AIHW), a government entity based in Australia, revealed in July 2024 that cancer diagnoses in the country increased from 160,570 instances in 2022 to 164,694 instances in 2023, reflecting a notable year-over-year rise. Consequently, the escalating prevalence of cancer is fueling the growth of the personalized cancer vaccine market.

Personalized Cancer Vaccines Market Segments: Where Are The Largest Growth Opportunities?

The personalized cancer vaccines market covered in this report is segmented –

1) By Treatment Type: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines

2) By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Prostate Cancer, Cervical Cancer, Glioblastoma

3) By Mechanism Of Action: Tumor Associated Antigens (TAAs), Tumor Specific Antigens (TSAs), Somatic Mutations In Cancer Pharmacogenomics, Pharmacogenomics Towards Genomic Polymorphism, Other Mechanisms Of Action

4) By Route Of Administration: Injectables, Other Routes Of Administration

5) By End Use: Hospitals, Clinic, Other End Users

Subsegments:

1) By Preventive Cancer Vaccines: HPV Vaccines, Hepatitis B Vaccines, Combination Vaccines

2) By Therapeutic Cancer Vaccines: Dendritic Cell Vaccines, Peptide-Based Vaccines, DNA Vaccines, RNA Vaccines, Whole Cell Vaccines

Personalized Cancer Vaccines Market Industry Trends Shaping Future Revenue Growth

Leading players in the personalized cancer vaccine space are concentrating their efforts on creating advanced therapeutic approaches, such as tailored immunotherapies that target tumor mutations unique to each patient, with the goal of boosting treatment accuracy and enhancing clinical results. Personalized immunotherapy involves customized cancer treatments that leverage a patient’s individual genetic and tumor mutation data, often delivered through dendritic cell-based vaccines or neoantigen-targeting systems, to trigger a specifically adapted immune response against malignant cells. For example, in August 2024, UCLA Health, a US-based healthcare organization, initiated a groundbreaking clinical trial for a personalized cancer vaccine addressing the H3 G34 mutation in diffuse hemispheric gliomas. This approach employs dendritic cells to foster immunity against the RNA disruptions caused by this aggressive mutation, opening up a promising therapeutic avenue for adolescents and young adults, who generally face limited treatment options and poor survival prospects.

Personalized Cancer Vaccines Market Major Participants And Competitive Dynamics

Major companies operating in the personalized cancer vaccines market are Moderna Inc., CureVac AG, BioNTech SE, Genentech Inc., Merck & Co. Inc., GlaxoSmithKline plc, Achilles Therapeutics Plc, Evaxion Biotech AS, Geneos Therapeutics Inc., ISA Pharmaceuticals BV, VAXIMM GmbH, EpiVax Therapeutics Inc., Personalis Inc., Catalent Inc., Gritstone bio Inc., Neon Therapeutics Inc., Nouscom AG, Vaccitech plc, Agenus Inc., Transgene SA

Access The Complete Personalized Cancer Vaccines Market Report:

https://www.thebusinessresearchcompany.com/report/personalized-cancer-vaccines-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Personalized Cancer Vaccines Market Geographic Analysis: Where Is Demand Growing The Fastest?

North America was the largest region in the personalized cancer vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized cancer vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Will The Market Value Of The Personalized Cancer Vaccines Market Change Between 2026 And 2030?

The personalized cancer vaccines market size has observed significant expansion over recent years. Its projected growth will take it from $256.65 billion in 2025 to $273.05 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 6.4%. This historical market expansion can be attributed to several factors, including advances in cancer genomics, the persistent unmet need in oncology treatments, the inherent limitations of traditional cancer therapies, the increasing volume of immunotherapy research, and enhanced funding allocated to cancer research.

The personalized cancer vaccines market is projected for substantial expansion in the coming years, with its size expected to reach $350.3 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.4%. This anticipated growth throughout the forecast period is driven by factors such as the increasing adoption of personalized medicine, rising cancer incidence rates, advancements in neoantigen discovery, growing collaboration among biotech firms, and supportive regulatory frameworks. Major trends expected during this period include a heightened focus on personalized immunotherapy, a rise in the use of genomic tumor profiling, the expansion of therapeutic cancer vaccines, increasing integration with precision oncology, and more extensive clinical trial activity in cancer vaccines.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19136&type=smp

What Key Growth Drivers Are Influencing The Personalized Cancer Vaccines Market?

The rising incidence of cancer is anticipated to fuel the expansion of the personalized cancer vaccine market in the future. Cancer encompasses a category of illnesses marked by unregulated cell proliferation, capable of infiltrating adjacent tissues and metastasizing throughout the body. The growing occurrence of cancer is fueled by factors such as demographic shifts towards older populations, evolving lifestyles, exposure to environmental hazards, and advancements in diagnostic methods. The personalized cancer vaccine market contributes to oncology care by providing vaccines customized to an individual patient’s tumor antigens, thereby bolstering the immune system’s capacity to recognize and eradicate malignant cells. For example, data released in July 2024 by the Australian Institute of Health and Welfare (AIHW), an Australia-based government body, showed that cancer diagnoses in Australia climbed from 160,570 cases in 2022 to 164,694 cases in 2023, representing a notable year-on-year rise. Consequently, the growing frequency of cancer cases is stimulating the development of the personalized cancer vaccine market.

Which Segment Groups Define The Personalized Cancer Vaccines Market Landscape?

The personalized cancer vaccines market covered in this report is segmented –

1) By Treatment Type: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines

2) By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Prostate Cancer, Cervical Cancer, Glioblastoma

3) By Mechanism Of Action: Tumor Associated Antigens (TAAs), Tumor Specific Antigens (TSAs), Somatic Mutations In Cancer Pharmacogenomics, Pharmacogenomics Towards Genomic Polymorphism, Other Mechanisms Of Action

4) By Route Of Administration: Injectables, Other Routes Of Administration

5) By End Use: Hospitals, Clinic, Other End Users

Subsegments:

1) By Preventive Cancer Vaccines: HPV Vaccines, Hepatitis B Vaccines, Combination Vaccines

2) By Therapeutic Cancer Vaccines: Dendritic Cell Vaccines, Peptide-Based Vaccines, DNA Vaccines, RNA Vaccines, Whole Cell Vaccines

What Trends Are Affecting The Growth Of The Personalized Cancer Vaccines Market?

Leading firms within the personalized cancer vaccine market are concentrating on creating cutting-edge therapeutic approaches, specifically personalized immunotherapy tailored to address individual patient tumor mutations, with the aim of boosting treatment accuracy and achieving better clinical results. This personalized immunotherapy involves bespoke cancer therapies that leverage a patient’s unique genetic and tumor mutation information, frequently administered via dendritic cell-based vaccines or neoantigen-targeting systems, to elicit a specific immune reaction against cancerous cells. As an illustration, in August 2024, UCLA Health, a healthcare entity based in the US, initiated an unprecedented clinical trial to assess a personalized cancer vaccine. This vaccine targets the H3 G34 mutation found in diffuse hemispheric gliomas, employing dendritic cells to provoke an immune response against the RNA irregularities induced by this severe mutation, thereby presenting a hopeful treatment avenue for adolescents and young adults who commonly face restricted treatment alternatives and low survival prospects.

Which Companies Are Influencing The Personalized Cancer Vaccines Market?

Major companies operating in the personalized cancer vaccines market are Moderna Inc., CureVac AG, BioNTech SE, Genentech Inc., Merck & Co. Inc., GlaxoSmithKline plc, Achilles Therapeutics Plc, Evaxion Biotech AS, Geneos Therapeutics Inc., ISA Pharmaceuticals BV, VAXIMM GmbH, EpiVax Therapeutics Inc., Personalis Inc., Catalent Inc., Gritstone bio Inc., Neon Therapeutics Inc., Nouscom AG, Vaccitech plc, Agenus Inc., Transgene SA

Access The Complete Personalized Cancer Vaccines Market Report:

https://www.thebusinessresearchcompany.com/report/personalized-cancer-vaccines-global-market-report

Which Region Holds The Largest Share In The Personalized Cancer Vaccines Market?

North America was the largest region in the personalized cancer vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized cancer vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Personalized Cancer Vaccines Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=19136&type=smp

Browse Through More Reports Similar to the Global Personalized Cancer Vaccines Market 2026, By The Business Research Company

Therapeutic Bcg Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

Cervical Cancer Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/cervical-cancer-vaccine-global-market-report

Dendritic Cell Cancer Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/dendritic-cell-cancer-vaccine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Personalized Cancer Vaccines Market Expected To Change From 2026 To 2030?

The personalized cancer vaccines market has demonstrated robust expansion over recent years. Projections indicate its size will increase from $256.65 billion in 2025 to $273.05 billion by 2026, advancing at a compound annual growth rate (CAGR) of 6.4%. Historically, this growth can be attributed to advances in cancer genomics, the unmet need in oncology treatments, limitations of traditional cancer therapies, the growth in immunotherapy research, and increased funding for cancer research.

The personalized cancer vaccines market size is anticipated to experience robust growth in the upcoming years. It is projected to expand to $350.3 billion by 2030, achieving a compound annual growth rate (CAGR) of 6.4%. This expansion during the forecast period is attributable to the wider adoption of personalized medicine, rising cancer incidence rates, advancements in neoantigen discovery, increasing collaborations among biotech firms, and supportive regulatory frameworks. Prominent trends expected in this period encompass a growing emphasis on personalized immunotherapy, greater utilization of genomic tumor profiling, the expansion of therapeutic cancer vaccines, increasing integration with precision oncology, and heightened clinical trial activity in cancer vaccines.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19136&type=smp

Which Strong Drivers Are Impacting The Personalized Cancer Vaccines Market Growth?

The rising incidence of cancer is projected to fuel the expansion of the personalized cancer vaccine market moving forward. Cancer describes a range of illnesses characterized by uncontrolled cell division that can invade adjacent tissues and spread to other areas of the body. The increasing prevalence of cancer is influenced by factors such as aging populations, lifestyle modifications, environmental exposures, and improved diagnostic capabilities. The personalized cancer vaccine market aids cancer care by offering vaccines customized to patient-specific tumor antigens, thereby enhancing the immune system’s ability to detect and eliminate cancer cells. For instance, in July 2024, as per the Australian Institute of Health and Welfare (AIHW), an Australia-based government agency, cancer diagnoses in Australia increased from 160,570 cases in 2022 to 164,694 cases in 2023, showing a significant year-over-year rise. Therefore, the growing prevalence of cancer is a key driver for the personalized cancer vaccine market’s growth.

Which Segments Define The Personalized Cancer Vaccines Market Segment Structure?

The personalized cancer vaccines market covered in this report is segmented –

1) By Treatment Type: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines

2) By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Prostate Cancer, Cervical Cancer, Glioblastoma

3) By Mechanism Of Action: Tumor Associated Antigens (TAAs), Tumor Specific Antigens (TSAs), Somatic Mutations In Cancer Pharmacogenomics, Pharmacogenomics Towards Genomic Polymorphism, Other Mechanisms Of Action

4) By Route Of Administration: Injectables, Other Routes Of Administration

5) By End Use: Hospitals, Clinic, Other End Users

Subsegments:

1) By Preventive Cancer Vaccines: HPV Vaccines, Hepatitis B Vaccines, Combination Vaccines

2) By Therapeutic Cancer Vaccines: Dendritic Cell Vaccines, Peptide-Based Vaccines, DNA Vaccines, RNA Vaccines, Whole Cell Vaccines

Which Trends Are Influencing Demand In The Personalized Cancer Vaccines Market?

Leading companies in the personalized cancer vaccine market are concentrating on creating advanced therapeutic solutions. These solutions include personalized immunotherapy, which is designed to specifically target patient tumor mutations, aiming to improve treatment accuracy and clinical results. Personalized immunotherapy describes custom cancer treatments that utilize a patient’s unique genetic and tumor mutation profile, frequently administered through dendritic cell-based vaccines or neoantigen-targeted platforms, to stimulate a specific immune response against malignant cells. As an illustration, in August 2024, UCLA Health, a healthcare organization based in the US, initiated a groundbreaking clinical trial. This trial is assessing a personalized cancer vaccine that targets the H3 G34 mutation in diffuse hemispheric gliomas. It uses dendritic cells to activate immunity against RNA disruptions caused by this aggressive mutation, offering a promising treatment option for adolescents and young adults who typically face limited treatment choices and poor survival rates.

Who Are The Established Players Within The Personalized Cancer Vaccines Market?

Major companies operating in the personalized cancer vaccines market are Moderna Inc., CureVac AG, BioNTech SE, Genentech Inc., Merck & Co. Inc., GlaxoSmithKline plc, Achilles Therapeutics Plc, Evaxion Biotech AS, Geneos Therapeutics Inc., ISA Pharmaceuticals BV, VAXIMM GmbH, EpiVax Therapeutics Inc., Personalis Inc., Catalent Inc., Gritstone bio Inc., Neon Therapeutics Inc., Nouscom AG, Vaccitech plc, Agenus Inc., Transgene SA

Get The Full Personalized Cancer Vaccines Market Report:

https://www.thebusinessresearchcompany.com/report/personalized-cancer-vaccines-global-market-report

Where Is The Personalized Cancer Vaccines Market Most Concentrated Geographically?

North America was the largest region in the personalized cancer vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized cancer vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Personalized Cancer Vaccines Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/personalized-cancer-vaccines-global-market-report

Browse Through More Reports Similar to the Global Personalized Cancer Vaccines Market 2026, By The Business Research Company

Therapeutic Bcg Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

Cervical Cancer Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/cervical-cancer-vaccine-global-market-report

Dendritic Cell Cancer Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/dendritic-cell-cancer-vaccine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Valuation Is Forecasted For The Personalized Cancer Vaccines Market By 2030 Starting From Its 2026 Size?

The personalized cancer vaccines market size has demonstrated robust growth in recent years. It is anticipated to increase from $256.65 billion in 2025 to $273.05 billion in 2026, at a compound annual growth rate (CAGR) of 6.4%. This historical expansion can be attributed to advancements in cancer genomics, the unmet need in oncology treatments, the limitations of traditional cancer therapies, the surge in immunotherapy research, and heightened funding for cancer research.

The personalized cancer vaccines market is projected to experience substantial expansion over the upcoming years. By 2030, its size is anticipated to reach $350.3 billion, demonstrating a compound annual growth rate (CAGR) of 6.4%. This projected growth during the forecast period is primarily driven by factors such as the wider adoption of personalized medicine, an increase in cancer incidence rates, advancements in neoantigen discovery, growing partnerships among biotech companies, and favorable regulatory environments. Key trends anticipated in this period encompass an elevated focus on personalized immunotherapy, the expanded application of genomic tumor profiling, the development of therapeutic cancer vaccines, increased integration with precision oncology, and a surge in clinical trial activities for cancer vaccines.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19136&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Personalized Cancer Vaccines Market?

The increasing occurrence of cancer is anticipated to fuel the expansion of the personalized cancer vaccine market in the future. Cancer refers to a variety of diseases marked by unregulated cell proliferation that can infiltrate adjacent tissues and spread throughout the body. The escalating prevalence of cancer is driven by aging demographics, evolving lifestyle patterns, environmental exposures, and advancements in diagnostic methods. The personalized cancer vaccine market supports cancer care by providing vaccines tailored to patient-specific tumor antigens, thereby strengthening the immune system’s ability to detect and eradicate cancer cells. For instance, in July 2024, according to the Australian Institute of Health and Welfare (AIHW), an Australia-based government agency, cancer diagnoses in Australia rose from 160,570 cases in 2022 to 164,694 cases in 2023, indicating a significant year-over-year increase. Consequently, the rising prevalence of cancer is a key factor driving the growth of the personalized cancer vaccine market.

Which Segment Categories Define The Personalized Cancer Vaccines Market?

The personalized cancer vaccines market covered in this report is segmented –

1) By Treatment Type: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines

2) By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Prostate Cancer, Cervical Cancer, Glioblastoma

3) By Mechanism Of Action: Tumor Associated Antigens (TAAs), Tumor Specific Antigens (TSAs), Somatic Mutations In Cancer Pharmacogenomics, Pharmacogenomics Towards Genomic Polymorphism, Other Mechanisms Of Action

4) By Route Of Administration: Injectables, Other Routes Of Administration

5) By End Use: Hospitals, Clinic, Other End Users

Subsegments:

1) By Preventive Cancer Vaccines: HPV Vaccines, Hepatitis B Vaccines, Combination Vaccines

2) By Therapeutic Cancer Vaccines: Dendritic Cell Vaccines, Peptide-Based Vaccines, DNA Vaccines, RNA Vaccines, Whole Cell Vaccines

What Major Market Trends Are Driving Changes In The Personalized Cancer Vaccines Market?

Major companies operating in the personalized cancer vaccine market are focusing on developing advanced therapeutic solutions, such as personalized immunotherapy designed to target patient-specific tumor mutations, to enhance treatment precision and improve clinical outcomes. Personalized immunotherapy refers to customized cancer treatments that use a patient’s own genetic and tumor mutation profile often delivered through dendritic cell–based vaccines or neoantigen-targeted platforms to activate a tailored immune response against malignant cells. For instance, in August 2024, UCLA Health, a US-based healthcare organization, launched a first-of-its-kind clinical trial evaluating a personalized cancer vaccine that targets the H3 G34 mutation in diffuse hemispheric gliomas, using dendritic cells to stimulate immunity against the RNA disruptions caused by this aggressive mutation, offering a promising therapeutic option for adolescents and young adults who typically have limited treatment choices and poor survival rates.

Who Are The Top Companies Competing In The Personalized Cancer Vaccines Market?

Major companies operating in the personalized cancer vaccines market are Moderna Inc., CureVac AG, BioNTech SE, Genentech Inc., Merck & Co. Inc., GlaxoSmithKline plc, Achilles Therapeutics Plc, Evaxion Biotech AS, Geneos Therapeutics Inc., ISA Pharmaceuticals BV, VAXIMM GmbH, EpiVax Therapeutics Inc., Personalis Inc., Catalent Inc., Gritstone bio Inc., Neon Therapeutics Inc., Nouscom AG, Vaccitech plc, Agenus Inc., Transgene SA

Read the full personalized cancer vaccines market report here:

https://www.thebusinessresearchcompany.com/report/personalized-cancer-vaccines-global-market-report

Which Regions Are Projected To Dominate The Personalized Cancer Vaccines Market In The Coming Years?

North America was the largest region in the personalized cancer vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized cancer vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Personalized Cancer Vaccines Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19136&type=smp

Browse Through More Reports Similar to the Global Personalized Cancer Vaccines Market 2026, By The Business Research Company

Therapeutic Bcg Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

Cervical Cancer Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/cervical-cancer-vaccine-global-market-report

Dendritic Cell Cancer Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/dendritic-cell-cancer-vaccine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the personalized cancer vaccines market from 2026–2035 with trusted insights from The Business Research Company

How much larger will the Personalized Cancer Vaccines Market be in 2030 compared with 2026?

The personalized cancer vaccines market has demonstrated significant expansion in recent years. Its valuation is anticipated to rise from $256.65 billion in 2025 to $273.05 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.4%. This past growth is largely attributable to progress in cancer genomics, the existing unmet need in oncology treatments, the constraints of conventional cancer therapies, the rise in immunotherapy research, and increased financial support for cancer research.

The personalized cancer vaccines market size is anticipated to experience robust growth in the upcoming years. It is projected to expand to $350.3 billion by 2030, achieving a compound annual growth rate (CAGR) of 6.4%. The expansion observed during the forecast period can be attributed to factors such as the increasing adoption of personalized medicine, rising cancer incidence rates, advancements in neoantigen discovery, growing collaboration among biotech firms, and supportive regulatory frameworks. Significant trends expected during this period include a heightened focus on personalized immunotherapy, increased application of genomic tumor profiling, the broadening of therapeutic cancer vaccines, greater integration with precision oncology, and a surge in clinical trial activity for cancer vaccines.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19136&type=smp

What Drivers Are Guiding Growth Patterns In The Personalized Cancer Vaccines Market?

The expanding occurrence of cancer is projected to fuel the growth of the personalized cancer vaccine market in the future. Cancer is defined as a collection of illnesses marked by unchecked cell proliferation, capable of infiltrating adjacent tissues and metastasizing throughout the body. The rising incidence of cancer is attributed to an aging global populace, shifts in lifestyle, exposure to environmental factors, and enhanced diagnostic tools. This market assists cancer treatment by offering vaccines customized to individual patient tumor antigens, thereby boosting the immune system’s capacity to recognize and eradicate cancerous cells. For example, in July 2024, the Australian Institute of Health and Welfare (AIHW), an Australia-based government agency, reported that cancer diagnoses in Australia escalated from 160,570 cases in 2022 to 164,694 cases in 2023, indicating a significant year-over-year increase. Consequently, the escalating prevalence of cancer is driving the expansion of the personalized cancer vaccine market.

How Is The Personalized Cancer Vaccines Market Divided Into Segments?

The personalized cancer vaccines market covered in this report is segmented –

1) By Treatment Type: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines

2) By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Prostate Cancer, Cervical Cancer, Glioblastoma

3) By Mechanism Of Action: Tumor Associated Antigens (TAAs), Tumor Specific Antigens (TSAs), Somatic Mutations In Cancer Pharmacogenomics, Pharmacogenomics Towards Genomic Polymorphism, Other Mechanisms Of Action

4) By Route Of Administration: Injectables, Other Routes Of Administration

5) By End Use: Hospitals, Clinic, Other End Users

Subsegments:

1) By Preventive Cancer Vaccines: HPV Vaccines, Hepatitis B Vaccines, Combination Vaccines

2) By Therapeutic Cancer Vaccines: Dendritic Cell Vaccines, Peptide-Based Vaccines, DNA Vaccines, RNA Vaccines, Whole Cell Vaccines

Which Trends Are Expected To Influence The Personalized Cancer Vaccines Market In The Upcoming Years?

Major companies operating within the personalized cancer vaccine market are concentrating on creating advanced therapeutic solutions, such as personalized immunotherapy designed to target tumor mutations specific to individual patients, with the goal of improving treatment accuracy and enhancing clinical results. Personalized immunotherapy is defined as customized cancer treatments that utilize a patient’s unique genetic and tumor mutation profile, often administered through dendritic cell–based vaccines or neoantigen-targeted platforms, to activate a tailored immune response against malignant cells. For instance, in August 2024, UCLA Health, a US-based healthcare organization, initiated an unprecedented clinical trial assessing a personalized cancer vaccine that targets the H3 G34 mutation in diffuse hemispheric gliomas, employing dendritic cells to stimulate immunity against the RNA disruptions caused by this aggressive mutation, thereby presenting a promising therapeutic alternative for adolescents and young adults who typically face limited treatment choices and poor survival rates.

Which Major Firms Are Strengthening Their Position In The Personalized Cancer Vaccines Market?

Major companies operating in the personalized cancer vaccines market are Moderna Inc., CureVac AG, BioNTech SE, Genentech Inc., Merck & Co. Inc., GlaxoSmithKline plc, Achilles Therapeutics Plc, Evaxion Biotech AS, Geneos Therapeutics Inc., ISA Pharmaceuticals BV, VAXIMM GmbH, EpiVax Therapeutics Inc., Personalis Inc., Catalent Inc., Gritstone bio Inc., Neon Therapeutics Inc., Nouscom AG, Vaccitech plc, Agenus Inc., Transgene SA

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/personalized-cancer-vaccines-global-market-report

Which Region Shows The Strongest Potential For Future Expansion In The Personalized Cancer Vaccines Market?

North America was the largest region in the personalized cancer vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized cancer vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Personalized Cancer Vaccines Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19136&type=smp

Browse Through More Reports Similar to the Global Personalized Cancer Vaccines Market 2026, By The Business Research Company

Therapeutic Bcg Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

Cervical Cancer Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/cervical-cancer-vaccine-global-market-report

Dendritic Cell Cancer Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/dendritic-cell-cancer-vaccine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the parenteral nutrition market from 2025–2034 with trusted insights from The Business Research Company

What Is The Present Size Of The Parenteral Nutrition Market And What Value Is Projected For 2029?

The personalized cancer vaccines market size has shown strong expansion in recent years. It is anticipated to expand from $242.29 billion in 2024 to $256.65 billion in 2025, with a compound annual growth rate (CAGR) of 5.9%. This historical growth can be attributed to progress in genomic research, the evolution of targeted therapies, a deeper understanding of tumor immunology, improvements in vaccine technology, and increasing clinical trial data that supports efficacy.

The personalized cancer vaccines market is projected to undergo substantial expansion in the coming years. It is anticipated to grow to $329.04 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 6.4%. This expected growth within the forecast period can be attributed to progress in precision medicine, increased funding directed towards cancer research, the rising incidence of cancer cases, enhancements in genetic sequencing technologies, and a growing interest in tailored treatment options. Major developments projected for this period include the integration of artificial intelligence into vaccine design, advancements in vaccines based on multi-antigens and neoantigens, a broader application of liquid biopsies for tumor surveillance, the expansion of combination therapies, and a heightened focus on individualized treatment regimens.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19136&type=smp

What Factors Are Boosting The Parenteral Nutrition Market?

The expanding occurrence of cancer is projected to fuel the advancement of the personalized cancer vaccine market going forward. Cancer is defined as a group of illnesses characterized by uncontrolled cellular proliferation capable of metastasizing to various bodily regions. This rise in cancer cases stems from factors such as an aging demographic, shifts in lifestyle, exposure to environmental contaminants, inherited genetic tendencies, and enhanced diagnostic methods. Personalized cancer vaccines contribute to mitigating the growing incidence of cancer by focusing on tumor antigens distinct to every patient, thereby boosting the immune system’s capacity to identify and eliminate malignant cells. As an illustration, data from July 2024, provided by the Australian Institute of Health and Welfare, a government body located in Australia, showed that in Australia, cancer diagnoses climbed from 160,570 in 2022 to 164,694 in 2023, indicating a significant year-over-year increase. Consequently, the rising occurrence of cancer serves as a key impetus for the expansion of the personalized cancer vaccine market.

What Are The Core Segmentation Criteria In The Parenteral Nutrition Market?

The personalized cancer vaccines market covered in this report is segmented –

1) By Treatment Type: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines

2) By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Prostate Cancer, Cervical Cancer, Glioblastoma

3) By Mechanism Of Action: Tumor Associated Antigens (TAAs), Tumor Specific Antigens (TSAs), Somatic Mutations In Cancer Pharmacogenomics, Pharmacogenomics Towards Genomic Polymorphism, Other Mechanisms Of Action

4) By Route Of Administration: Injectables, Other Routes Of Administration

5) By End Use: Hospitals, Clinic, Other End Users

Subsegments:

1) By Preventive Cancer Vaccines: HPV Vaccines, Hepatitis B Vaccines, Combination Vaccines

2) By Therapeutic Cancer Vaccines: Dendritic Cell Vaccines, Peptide-Based Vaccines, DNA Vaccines, RNA Vaccines, Whole Cell Vaccines

Which Emerging Trends Are Reshaping The Parenteral Nutrition Market Landscape?

Leading companies in the personalized cancer vaccine market are prioritizing the creation of advanced therapeutic solutions, such as personalized immunotherapy, to improve the precision of treating specific cancer mutations. Personalized immunotherapy involves customized treatments designed to utilize a patient’s unique genetic and tumor characteristics to enhance immune system responses against cancer. For example, in August 2024, UCLA Health, a US-based healthcare organization, initiated a groundbreaking clinical trial to assess the safety and effectiveness of a cancer vaccine. The vaccine, developed at UCLA, employs a personalized immunotherapy strategy that targets the H3 G34 mutation found in diffuse hemispheric gliomas, an extremely aggressive brain tumor frequently observed in adolescents and young adults. It distinctively uses dendritic cells to activate the immune system in response to the specific RNA disruptions caused by this mutation. This strategy, which has shown encouraging results in treating other cancers, aims to improve outcomes for patients who typically face limited treatment options and shorter survival durations.

Which Players Are Shaping The Competitive Landscape Of The Parenteral NutritionXX Market?

Major companies operating in the personalized cancer vaccines market are Merck & Co Inc., GlaxoSmithKline Plc, NEC Corporation, Moderna Inc., Catalent Inc., UCLA Health, Genetech Inc., NHS England, CureVac AG, Personalis Inc., Achilles Therapeutics Plc, Healio, Moffitt Corporation, BioPharma APAC, Celebrity Angels, EpiVax Therapeutics Inc., Evaxion Biotech AS, Geneos Therapeutics Inc., IFL Sciense, ISA Pharmaceuticals BV, Oxford Global, Kintara Therapeutics, VAXIMM Gmbh

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/personalized-cancer-vaccines-global-market-report

What Regional Trends Are Shaping Growth In The Parenteral Nutrition Market?

North America was the largest region in the personalized cancer vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized cancer vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=19136&type=smp

Browse Through More Reports Similar to the Global Parenteral Nutrition Market 2025, By The Business Research Company

Cancer Vaccine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-vaccine-global-market-report

Cervical Cancer Vaccine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cervical-cancer-vaccine-global-market-report

Cancer Biologics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Growth Projections For The Personalized Cancer Vaccines Market Size During 2025–2029?

The personalized cancer vaccines market size has shown substantial growth in recent years. It is anticipated to increase from $242.29 billion in 2024 to $256.65 billion in 2025, reflecting a compound annual growth rate (CAGR) of 5.9%. This expansion in the past can be linked to breakthroughs in genomic research, the creation of targeted therapies, a deeper insight into tumor immunology, improvements in vaccine technology, and accumulating clinical trial data that validates efficacy.

The personalized cancer vaccines market is anticipated to experience substantial expansion over the upcoming years. This market is projected to reach $329.04 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.4%. Factors contributing to this growth during the forecast period include advancements in precision medicine, increased funding for cancer research, a rising prevalence of cancer cases, enhancements in genetic sequencing technologies, and a heightened interest in customized treatment solutions. Key trends expected within the forecast period encompass the integration of artificial intelligence into vaccine design, breakthroughs in multi-antigen and neoantigen-based vaccines, a rise in the application of liquid biopsies for monitoring tumors, the broadening of combination therapies, and an intensified emphasis on tailored treatment regimens.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19136&type=smp

Which Factors And Drivers Are Influencing The Personalized Cancer Vaccines Market In 2025?

The rise in cancer cases is anticipated to drive expansion in the personalized cancer vaccine market moving ahead. Cancer is defined as a group of illnesses characterized by uncontrolled cell proliferation capable of spreading throughout the body. This growing incidence of cancer stems from factors such as an aging demographic, shifts in lifestyle, exposure to environmental contaminants, genetic vulnerabilities, and enhanced diagnostic methodologies. Personalized cancer vaccines play a role in mitigating the rising prevalence of cancer by targeting tumor antigens specific to individual patients, thereby boosting the immune system’s capacity to identify and eliminate malignant cells. For example, in July 2024, data from the Australian Institute of Health and Welfare, an Australia-based government agency, indicated that in Australia, cancer diagnoses climbed from 160,570 in 2022 to 164,694 in 2023, showing a significant increase within that year. Consequently, the expanding occurrence of cancer is a key factor fueling the development of the personalized cancer vaccine market.

What Are The Segment Types Shaping The Personalized Cancer Vaccines Market?

The personalized cancer vaccines market covered in this report is segmented –

1) By Treatment Type: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines

2) By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Prostate Cancer, Cervical Cancer, Glioblastoma

3) By Mechanism Of Action: Tumor Associated Antigens (TAAs), Tumor Specific Antigens (TSAs), Somatic Mutations In Cancer Pharmacogenomics, Pharmacogenomics Towards Genomic Polymorphism, Other Mechanisms Of Action

4) By Route Of Administration: Injectables, Other Routes Of Administration

5) By End Use: Hospitals, Clinic, Other End Users

Subsegments:

1) By Preventive Cancer Vaccines: HPV Vaccines, Hepatitis B Vaccines, Combination Vaccines

2) By Therapeutic Cancer Vaccines: Dendritic Cell Vaccines, Peptide-Based Vaccines, DNA Vaccines, RNA Vaccines, Whole Cell Vaccines

How Are Trends Influencing The Personalized Cancer Vaccines Market?

Leading companies operating in the personalized cancer vaccine market are primarily focused on advancing therapeutic solutions, including personalized immunotherapy, to enhance the precision of treatment for specific cancer mutations. Personalized immunotherapy solutions represent customized treatments designed to utilize a patient’s unique genetic and tumor characteristics to bolster immune system responses against cancer. For example, in August 2024, UCLA Health, a healthcare organization based in the US, commenced a groundbreaking clinical trial to evaluate the safety and effectiveness of a new cancer vaccine. This vaccine, developed at UCLA, employs a personalized immunotherapy approach that specifically targets the H3 G34 mutation in diffuse hemispheric gliomas, an aggressive brain tumor commonly affecting adolescents and young adults. Its unique mechanism involves using dendritic cells to activate the immune system against the specific RNA disruptions induced by this mutation. The approach, which has shown promise in treating other cancers, aims to improve outcomes for patients who typically face limited treatment options and short survival times.

Who Are The Core Companies Influencing The Personalized Cancer Vaccines Market Landscape?

Major companies operating in the personalized cancer vaccines market are Merck & Co Inc., GlaxoSmithKline Plc, NEC Corporation, Moderna Inc., Catalent Inc., UCLA Health, Genetech Inc., NHS England, CureVac AG, Personalis Inc., Achilles Therapeutics Plc, Healio, Moffitt Corporation, BioPharma APAC, Celebrity Angels, EpiVax Therapeutics Inc., Evaxion Biotech AS, Geneos Therapeutics Inc., IFL Sciense, ISA Pharmaceuticals BV, Oxford Global, Kintara Therapeutics, VAXIMM Gmbh

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/personalized-cancer-vaccines-global-market-report

Which Geographies Are Emerging As Strong Markets For The Personalized Cancer Vaccines Industry?

North America was the largest region in the personalized cancer vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized cancer vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Personalized Cancer Vaccines Market Report:

https://www.thebusinessresearchcompany.com/customise?id=19136&type=smp

Browse Through More Reports Similar to the Global Personalized Cancer Vaccines Market 2025, By The Business Research Company

Cancer Vaccine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-vaccine-global-market-report

Cervical Cancer Vaccine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cervical-cancer-vaccine-global-market-report

Cancer Biologics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Are The Future Growth Projections For The Personalized Cancer Vaccines Market Size?

The market for customized cancer vaccines has seen robust growth in the recent past. The size of the market is projected to rise from $242.29 billion in 2024 to $256.65 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 5.9%. The historic growth pattern is associated with progress in genomic research, the development of specifically targeted therapies, a more extensive grasp on tumor immunology, advancements in vaccine technology, and growing clinical trial data that supports efficacy.

The market for personalized cancer vaccines is anticipated to witness significant expansion in the coming years, reaching $329.04 billion in 2029 with an annual growth rate of 6.4%. This projected growth over the forecast period can be attributed to progress in precision medicine, heightened funding for cancer research, an increasing number of cancer cases, enhancements in genetic sequencing technologies, and a mounting interest in individualized treatment options. Key trends for the forecast period encompass the utilization of artificial intelligence in vaccine development, advancements in multi-antigen and neoantigen-based vaccines, the growing application of liquid biopsies for tumor surveillance, the broadening scope of combination therapies, and an intensified emphasis on personalized treatment plans.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19136&type=smp

Which Market Dynamics Are Playing A Critical Role In The Growth Of The Personalized Cancer Vaccines Market?

The escalating incidence of cancer worldwide is predicted to push forward the expansion of the personalized cancer vaccine sector. Cancer, characterized by anomalous cell growth with the ability to metastasize in the body, is becoming more pervasive due to aging demographics, alterations in lifestyle, exposure to environmental toxins, genetic predilections, and advanced diagnostic methods. Personalized cancer vaccines, which are aimed at specific tumor antigens unique to each patient, boost the immune system’s capacity to identify and eliminate cancerous cells, thus serving as a preventative measure against the rising prevalence of cancer. A case in point, data from the Australian Institute of Health and Welfare, a government agency in Australia, state that newly diagnosed cancer cases in Australia rose from 160,570 in 2022 to 164,694 in 2023, marking a significant year over year upswing. This increase in cancer prevalence is a contributing factor towards the development of the personalized cancer vaccine market.

Which Segmentation Factors Are Critical In The Personalized Cancer Vaccines Market Analysis?

The personalized cancer vaccines market covered in this report is segmented –

1) By Treatment Type: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines

2) By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Prostate Cancer, Cervical Cancer, Glioblastoma

3) By Mechanism Of Action: Tumor Associated Antigens (TAAs), Tumor Specific Antigens (TSAs), Somatic Mutations In Cancer Pharmacogenomics, Pharmacogenomics Towards Genomic Polymorphism, Other Mechanisms Of Action

4) By Route Of Administration: Injectables, Other Routes Of Administration

5) By End Use: Hospitals, Clinic, Other End Users

Subsegments:

1) By Preventive Cancer Vaccines: HPV Vaccines, Hepatitis B Vaccines, Combination Vaccines

2) By Therapeutic Cancer Vaccines: Dendritic Cell Vaccines, Peptide-Based Vaccines, DNA Vaccines, RNA Vaccines, Whole Cell Vaccines

What Are The Dominant Trends Currently Seen In The Personalized Cancer Vaccines Market?

Leading businesses within the personalized cancer vaccine market are concentrating on advancing therapeutic solutions like personalized immunotherapy, with an aim to increase precision in addressing specific cancer mutations. These personalized immunotherapy solutions are customized therapies constructed to take advantage of a patient’s unique genetic and tumor traits to augment the immune response to cancer. To illustrate, UCLA Health, a healthcare organization based in the US, initiated an unprecedented clinical trial in August 2024 to investigate the safety and efficacy of a novel cancer vaccine. The vaccine, developed by UCLA, capitalizes on a personalized immunotherapy method targeting the H3 G34 mutation in diffuse hemispheric gliomas. This brutal type of brain tumor is frequently found in adolescents and young adults. The vaccine uniquely engages dendritic cells to stimulate the immune system against the particular RNA disruptions instigated by this mutation. This strategy has proven potential in treating other kinds of cancer, and aims to enhance results for patients who usually have restricted treatment options and brief survival periods.

Which Players Are Shaping The Competitive Landscape Of The Personalized Cancer Vaccines Market?

Major companies operating in the personalized cancer vaccines market are Merck & Co Inc., GlaxoSmithKline Plc, NEC Corporation, Moderna Inc., Catalent Inc., UCLA Health, Genetech Inc., NHS England, CureVac AG, Personalis Inc., Achilles Therapeutics Plc, Healio, Moffitt Corporation, BioPharma APAC, Celebrity Angels, EpiVax Therapeutics Inc., Evaxion Biotech AS, Geneos Therapeutics Inc., IFL Sciense, ISA Pharmaceuticals BV, Oxford Global, Kintara Therapeutics, VAXIMM Gmbh

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/personalized-cancer-vaccines-global-market-report

Which Region Is Likely To Register The Fastest Growth In The Personalized Cancer Vaccines Market?

North America was the largest region in the personalized cancer vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized cancer vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=19136&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Outlook for the Parenteral Nutrition Market Heading Into 2029?

The market for personalized cancer vaccines has seen robust growth in recent years. The market is projected to expand from $242.29 billion in 2024 to $256.65 billion in 2025, with a compound annual growth rate (CAGR) of 5.9%. The historical growth in this market segment can be linked to improved genomic research, the creation of targeted therapies, enhanced knowledge of tumor immunology, advancements in vaccine technology, and an increase in clinical trial data showcasing effectiveness.

The market size of personalized cancer vaccines is predicted to experience robust expansion in the coming years, increasing to a substantial “$329.04 billion by 2029, with a compound annual growth rate (CAGR) of 6.4%.” Contributing factors to this expected surge include advancements in the field of precision medicine, heightened funds designated for cancer research, an upswing in cancer prevalence, enhancements in genetic sequencing techniques, and an increased emphasis on personalized healthcare. Future trends anticipated during this period are the incorporation of artificial intelligence in vaccine development, advancements in multi-antigen and neoantigen-based vaccines, growing utilization of liquid biopsies for tumor tracking, wider implementation of combination therapies, and a sharper focus on individualized treatment plans.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19136&type=smp

Which Factors Are Pushing The Parenteral Nutrition Market Forward?

The escalating incidences of malnutrition worldwide are propelling the expansion of the parenteral nutrition market. Malnutrition implies a deficiency, excess, or imbalance in the consumption of energy or nutrients by an individual. An increase in premature births leading to immune dysfunction and insufficient nutrition has stirred up the need for parenteral nutrition among babies and children. For instance, the United Nations International Children’s Emergency Fund, a US-based entity, stated in May 2023 that undernutrition is responsible for about half of all fatalities in children under the age of 5. Undernutrition escalates the susceptibility of children to common infections, heightens their severity, and prolongs recovery. Therefore, the surging incidences of malnutrition worldwide are anticipated to heighten the demand for parenteral nutrition during the forecast period.

The personalized cancer vaccines market covered in this report is segmented –

1) By Treatment Type: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines

2) By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Prostate Cancer, Cervical Cancer, Glioblastoma

3) By Mechanism Of Action: Tumor Associated Antigens (TAAs), Tumor Specific Antigens (TSAs), Somatic Mutations In Cancer Pharmacogenomics, Pharmacogenomics Towards Genomic Polymorphism, Other Mechanisms Of Action

4) By Route Of Administration: Injectables, Other Routes Of Administration

5) By End Use: Hospitals, Clinic, Other End Users

Subsegments:

1) By Preventive Cancer Vaccines: HPV Vaccines, Hepatitis B Vaccines, Combination Vaccines

2) By Therapeutic Cancer Vaccines: Dendritic Cell Vaccines, Peptide-Based Vaccines, DNA Vaccines, RNA Vaccines, Whole Cell Vaccines

What Future Market Trends Are Projected For The Parenteral Nutrition Industry?

Key players in the personalized cancer vaccine market are concentrating their efforts on creating innovative therapeutic solutions, like personalized immunotherapy, ensuring a more accurate approach to treating distinctive cancer mutations. Personalized immunotherapy treatments are tailored to make use of individual patient’s genetic composition and tumor attributes to augment the immune system’s fight against cancer. To illustrate, in August 2024, UCLA Health, a healthcare provider based in the United States, initiated an unprecedented clinical trial to appraise the safety and efficacy of a cancer vaccine. The novel vaccine, pioneered at UCLA, utilizes a personalized immunotherapy technique targeting the H3 G34 mutation typically found in diffuse hemispheric gliomas, a notably aggressive brain tumor commonly seen in young adults and teenagers. This strategy uniquely employs dendritic cells to spur the immune system into action against the distinctive RNA disruptions caused by this mutation. This approach, having demonstrated potential in other cancer treatments, aspires to better the prognosis for patients who ordinarily have very few treatment alternatives and a shorter lifespan.

Which Organizations Are Driving Progress In The Parenteral Nutrition Industry?

Major companies operating in the personalized cancer vaccines market are Merck & Co Inc., GlaxoSmithKline Plc, NEC Corporation, Moderna Inc., Catalent Inc., UCLA Health, Genetech Inc., NHS England, CureVac AG, Personalis Inc., Achilles Therapeutics Plc, Healio, Moffitt Corporation, BioPharma APAC, Celebrity Angels, EpiVax Therapeutics Inc., Evaxion Biotech AS, Geneos Therapeutics Inc., IFL Sciense, ISA Pharmaceuticals BV, Oxford Global, Kintara Therapeutics, VAXIMM Gmbh

https://www.thebusinessresearchcompany.com/report/personalized-cancer-vaccines-global-market-report

Which Region Is Expected To Experience The Highest Growth In The Parenteral Nutrition Industry?

North America was the largest region in the personalized cancer vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized cancer vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=19136&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model